



Abstract— Inflammation is a complex physiological 
phenomenon involving chemical and enzymatic mechanisms. 
Polymorphonuclear Neutrophil leukocytes (PMNs) play an 
important role by producing Reactive Oxygen Species (ROS) 
and releasing myeloperoxidase (MPO), a pro-oxidant enzyme. 
Released both in the phagolysosome and the extracellular 
medium, MPO produces during its peroxidase and 
halogenation cycles oxidant species, including hypochlorous 
acid, involved in the destruction of pathogen agents, like 
bacteria or viruses. Inflammatory pathologies, like rheumatoid 
arthritis, atherosclerosis,... induce an excessive stimulation of 
the PMNs and therefore an uncontrolled release of ROS and 
MPO in the extracellular medium, causing severe damages to 
surrounding tissues and biomolecules such as proteins, lipids 
and DNA. The treatment of chronic inflammatory pathologies 
remains a challenge. For many years, MPO has been used as a 
target for the development of effective treatments. Numerous 
studies have been focused on the design of new drugs 
presenting more efficient MPO inhibitory properties. 
However, some designed inhibitors can be toxic. An 
alternative consists in assessing the potential inhibitory action 
of clinically-known molecules, having an antioxidant activity. 
Propofol, 2,6-diisopropylphenol, which is used as intravenous 
anesthetic agent, meets these requirements. Besides its 
anesthetic action employed to induce sedative state during 
surgery or in intensive care units, propofol and its injectable 
form Diprivan indeed present antioxidant properties and act as 
ROS and free radical scavengers. A study has also evidenced 
the ability of propofol to inhibit the formation of the 
Neutrophil Extracellular Traps fibers, which are important to 
trap pathogen microorganisms during inflammation process.  
 
The aim of this study was to investigate the potential 
inhibitory action mechanism of propofol and Diprivan on 
MPO activity. To go into the anti-inflammatory action of 
propofol in depth, two of its oxidative derivatives, 2,6-
diisopropyl-1,4-p-benzquinone (PPFQ) and  3,5,3’,5’-
tetraisopropyl-(4,4’)-diphenoquinone (PPFDQ), were studied 
regarding their inhibitory action. Specific Immunological 
Extraction Followed by Enzyme Detection (SIEFED) and 
molecular modeling have evidenced the low anti-catalytic 
action of propofol. Stopped-flow absorption spectroscopy and 
direct MPO activity analysis have proved that propofol acts as  
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a reversible MPO inhibitor, by interacting as reductive 
substrate in the peroxidase cycle and promoting the 
accumulation of redox compound II. Overall, Diprivan 
exhibited a weaker inhibitory action than the active molecule, 
propofol. In contrast, PPFQ seemed to bind and obstruct the 
enzyme active site, preventing the trigger of the MPO oxidant 
cycles. PPFQ induced a better chlorination cycle inhibition at 
basic and neutral pH, in comparison to propofol. PPFDQ did 
not show any MPO inhibition activity. The three interest 
molecules have also demonstrated their inhibition ability on an 
important step of the inflammation pathway, the PMNs 
superoxide anions production, thanks to EPR spectroscopy 
and chemiluminescence. In conclusion, propofol presents an 
interesting immunomodulatory activity by acting as a 
reductive substrate in the peroxidase cycle of MPO, slowing 
down its activity, whereas PPFQ acts more as anti-catalytic 
substrate. Although PPFDQ has no impact on MPO, it can act 
on the inflammation process by inhibiting the superoxide 
anions production by PMNs. 
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